(Q36429727)

14 August 2017

1 reference

title

Novel treatment strategies for aggressive non-Hodgkin's lymphoma (English)

1 reference

14 August 2017

1

Luis Fayad

0 references

author name string

Anas Younes

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

733-748

1 reference

Combination sequential chemotherapy in advanced reticulum cell sarcoma

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Chemotherapy of localised histiocytic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

State-of-the-art therapeutics: diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

New molecular targets for treatment of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Receptor-mediated choreography of life and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

The soluble CD40 ligand sCD154 in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

The dynamics of life and death of malignant lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

BAFF and the regulation of B cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Potential for proteasome inhibition in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

OSCAR is an FcRgamma-associated receptor that is expressed by myeloid cells and is involved in antigen presentation and activation of human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

PI3K/Akt signalling pathway and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Analysis of the PI-3-Kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Mammalian target of rapamycin (mTOR) Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Targeting mTOR signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Will mTOR inhibitors make it as cancer drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Hsp90 isoforms: functions, expression and clinical importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

The Hsp90 chaperone complex as a novel target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

A hydrophobic segment within the C-terminal domain is essential for both client-binding and dimer formation of the HSP90-family molecular chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

The C-terminal half of Hsp90 is responsible for its cytoplasmic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Altered states: selectively drugging the Hsp90 cancer chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Overview: Translating Hsp90 Biology into Hsp90 Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Natural Product Origins of Hsp90 Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Heat shock protein 90 as a molecular target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Histone deacetylase inhibitors and cancer: from cell biology to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Clinical development of histone deacetylase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Histone deacetylase inhibitors open new doors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Rational development of histone deacetylase inhibitors as anticancer agents: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Aurora-A - a guardian of poles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Clinical anticancer drug development: targeting the cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Mechanism of Aurora B activation by INCENP and inhibition by hesperadin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Structure and function of Polo-like kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Expression of Polo-Like Kinase (PLK1) in non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Polo-like kinases and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Protein kinase C family functions in B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Thalidomide for patients with recurrent lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

Merkel Cell Carcinoma: Improved Outcome With the Addition of Adjuvant Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.733

21 January 2018

Identifiers

DOI

10.1517/14656566.7.6.733

1 reference

14 August 2017

1 reference